Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01654250 · ClinicalTrials.gov registry record · Phase 3
NWP09 in Children With Attention Deficit Hyperactivity Disorder (ADHD)
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 90
- Enrollment target
NCT01654250: Completed Phase 3 study, sponsored by Pfizer.
NCT01654250 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 90 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (88% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01654250, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 90 participants
- Enrollment target
Study Summary
The safety and efficacy of a chewable formulation of extended-release methylphenidate will be studied in children with ADHD
Primary Outcome
The SKAMP scale measured the manifestations of attention deficit hyperactivity disorder (ADHD) using an independent observer rating of the participant's impairment in classroom observed behaviors. SKAMP combined score comprised of 13 items (including subscales: attention with items 1-4, deportment with items 5-8, quality of work with items 9-11 and compliance with items 12-13). The SKAMP composite score was obtained by summing up each item score where each item was rated on a 7-point impairment
Interventions
- DRUG Placebo
- DRUG NWP09
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2012-07 |
| Est. Completion | 2012-10 |
| Phase | Phase 3 |
What the finished NCT01654250 record still lists
NCT01654250 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (88% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01654250 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01654250 about?
NCT01654250 is a clinical study titled "NWP09 in Children With Attention Deficit Hyperactivity Disorder (ADHD)". The safety and efficacy of a chewable formulation of extended-release methylphenidate will be studied in children with ADHD
What is the current status of trial NCT01654250?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 90 participants. The study started on 2012-07. Estimated completion is 2012-10.
What interventions are being tested in trial NCT01654250?
The interventions under investigation include: Placebo (DRUG), NWP09 (DRUG).
Who is sponsoring clinical trial NCT01654250?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01654250's enrollment target sits among peer trials
90 1724th of 2000 higher than 263 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia